Brelovitug clinical trials
Also written BJT-778.
How each study uses brelovitug is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the brelovitug studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 2 in phase 3
Studies that test brelovitug, phase 3 first.
- Jun 2027A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)Phase 3 · Mirum Pharmaceuticals, Inc.
- Aug 2027Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving BulevirtidePhase 2/3 · Mirum Pharmaceuticals, Inc.
Studies
Open first, then newest update. How each study uses brelovitug is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving BulevirtideRecruitingPhase 2/3Mirum Pharmaceuticals, Inc.NCT07454837Written as Brelovitug (BJT-778)
- A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)RecruitingPhase 3Mirum Pharmaceuticals, Inc.NCT07200908Written as Brelovitug 300 mg
- A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta InfectionActive, not recruitingPhase 2/3Mirum Pharmaceuticals, Inc.NCT06907290Written as Brelovitug 300 mg
- A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)Active, not recruitingPhase 3Mirum Pharmaceuticals, Inc.NCT07298330Written as Brelovitug 300 mg
Codes
What other systems call brelovitug · ClinicalTrials.gg INT014899
- UNII (FDA) 4M5NX28KQZBRELOVITUGOne source FDA
- NCI Thesaurus C224719BrelovitugOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 4M5NX28KQZ | BRELOVITUG | One source FDA |
| NCI Thesaurus | C224719 | Brelovitug | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.